Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC + Cadonilimab + SOX Conversion Therapy in Gastric Cancer with Peritoneal Metastasis
ChiCTR2400088619Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: R0 surgical conversion rate and Imaging examination results. Started Aug 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2400088619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088619.